Cargando…

Multimorbidity, polypharmacy and inappropriate prescribing in elderly patients with atrial fibrillation: A report from the China Atrial Fibrillation Registry Study

BACKGROUND: Multimorbidity, polypharmacy and inappropriate prescribing is common in elderly patients worldwide. We aimed to explore the current status of multimorbidity, polypharmacy and the appropriateness of pharmacological therapy among elderly patients with atrial fibrillation (AF) in China. MAT...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Xueyuan, Li, Mengmeng, Du, Xin, Jiang, Chenxi, Li, Songnan, Tang, Ribo, Sang, Caihua, Yu, Ronghui, Long, Deyong, Dong, Jianzeng, Ma, Changsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485537/
https://www.ncbi.nlm.nih.gov/pubmed/36148073
http://dx.doi.org/10.3389/fcvm.2022.988799
_version_ 1784792090436173824
author Guo, Xueyuan
Li, Mengmeng
Du, Xin
Jiang, Chenxi
Li, Songnan
Tang, Ribo
Sang, Caihua
Yu, Ronghui
Long, Deyong
Dong, Jianzeng
Ma, Changsheng
author_facet Guo, Xueyuan
Li, Mengmeng
Du, Xin
Jiang, Chenxi
Li, Songnan
Tang, Ribo
Sang, Caihua
Yu, Ronghui
Long, Deyong
Dong, Jianzeng
Ma, Changsheng
author_sort Guo, Xueyuan
collection PubMed
description BACKGROUND: Multimorbidity, polypharmacy and inappropriate prescribing is common in elderly patients worldwide. We aimed to explore the current status of multimorbidity, polypharmacy and the appropriateness of pharmacological therapy among elderly patients with atrial fibrillation (AF) in China. MATERIALS AND METHODS: We randomly selected 500 patients aged 65 years or older from the China AF Registry study. Multimorbidity was defined as ≥2 comorbidities and polypharmacy was defined as ≥5 long-term prescribed drugs. Appropriateness of prescribing was evaluated using the Screening Tool of Older People’s Prescriptions/Screening Tool to Alert to Right Treatment (STOPP/START) criteria version 2. Patients’ attitudes toward polypharmacy were evaluated by the Patients’ Attitudes Towards Deprescribing (PATD) questionnaire. RESULTS: Among the 500 patients included (mean age 75.2 ± 6.7 years, 49.0% male), 98.0% had multimorbidity and 49.4% had polypharmacy. The prevalence of potentially inappropriate medications (PIMs) and potential prescribing omissions (PPOs) was 43.6% (n = 218) and 71.6% (n = 358), respectively. Traditional Chinese medicine attributed largely to PIMs. Anticoagulants were the most common PPOs. Many clinical factors increased the risk of PIMs and PPOs. However, polypharmacy increased the risk of PIMs (OR 2.70, 95%CI 1.78–4.11; p < 0.0001), but not PPOs. In addition, 73.7% patients with polypharmacy were willing to have one or more of their medications prescribed if advised by their doctor. CONCLUSION: Multimorbidity and polypharmacy were highly prevalent in elderly patients with AF in China. A high prevalence of inappropriate prescribing was also observed. Therefore, much more attention should be paid to the serious health problem in the elderly population.
format Online
Article
Text
id pubmed-9485537
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94855372022-09-21 Multimorbidity, polypharmacy and inappropriate prescribing in elderly patients with atrial fibrillation: A report from the China Atrial Fibrillation Registry Study Guo, Xueyuan Li, Mengmeng Du, Xin Jiang, Chenxi Li, Songnan Tang, Ribo Sang, Caihua Yu, Ronghui Long, Deyong Dong, Jianzeng Ma, Changsheng Front Cardiovasc Med Cardiovascular Medicine BACKGROUND: Multimorbidity, polypharmacy and inappropriate prescribing is common in elderly patients worldwide. We aimed to explore the current status of multimorbidity, polypharmacy and the appropriateness of pharmacological therapy among elderly patients with atrial fibrillation (AF) in China. MATERIALS AND METHODS: We randomly selected 500 patients aged 65 years or older from the China AF Registry study. Multimorbidity was defined as ≥2 comorbidities and polypharmacy was defined as ≥5 long-term prescribed drugs. Appropriateness of prescribing was evaluated using the Screening Tool of Older People’s Prescriptions/Screening Tool to Alert to Right Treatment (STOPP/START) criteria version 2. Patients’ attitudes toward polypharmacy were evaluated by the Patients’ Attitudes Towards Deprescribing (PATD) questionnaire. RESULTS: Among the 500 patients included (mean age 75.2 ± 6.7 years, 49.0% male), 98.0% had multimorbidity and 49.4% had polypharmacy. The prevalence of potentially inappropriate medications (PIMs) and potential prescribing omissions (PPOs) was 43.6% (n = 218) and 71.6% (n = 358), respectively. Traditional Chinese medicine attributed largely to PIMs. Anticoagulants were the most common PPOs. Many clinical factors increased the risk of PIMs and PPOs. However, polypharmacy increased the risk of PIMs (OR 2.70, 95%CI 1.78–4.11; p < 0.0001), but not PPOs. In addition, 73.7% patients with polypharmacy were willing to have one or more of their medications prescribed if advised by their doctor. CONCLUSION: Multimorbidity and polypharmacy were highly prevalent in elderly patients with AF in China. A high prevalence of inappropriate prescribing was also observed. Therefore, much more attention should be paid to the serious health problem in the elderly population. Frontiers Media S.A. 2022-09-06 /pmc/articles/PMC9485537/ /pubmed/36148073 http://dx.doi.org/10.3389/fcvm.2022.988799 Text en Copyright © 2022 Guo, Li, Du, Jiang, Li, Tang, Sang, Yu, Long, Dong and Ma. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Guo, Xueyuan
Li, Mengmeng
Du, Xin
Jiang, Chenxi
Li, Songnan
Tang, Ribo
Sang, Caihua
Yu, Ronghui
Long, Deyong
Dong, Jianzeng
Ma, Changsheng
Multimorbidity, polypharmacy and inappropriate prescribing in elderly patients with atrial fibrillation: A report from the China Atrial Fibrillation Registry Study
title Multimorbidity, polypharmacy and inappropriate prescribing in elderly patients with atrial fibrillation: A report from the China Atrial Fibrillation Registry Study
title_full Multimorbidity, polypharmacy and inappropriate prescribing in elderly patients with atrial fibrillation: A report from the China Atrial Fibrillation Registry Study
title_fullStr Multimorbidity, polypharmacy and inappropriate prescribing in elderly patients with atrial fibrillation: A report from the China Atrial Fibrillation Registry Study
title_full_unstemmed Multimorbidity, polypharmacy and inappropriate prescribing in elderly patients with atrial fibrillation: A report from the China Atrial Fibrillation Registry Study
title_short Multimorbidity, polypharmacy and inappropriate prescribing in elderly patients with atrial fibrillation: A report from the China Atrial Fibrillation Registry Study
title_sort multimorbidity, polypharmacy and inappropriate prescribing in elderly patients with atrial fibrillation: a report from the china atrial fibrillation registry study
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485537/
https://www.ncbi.nlm.nih.gov/pubmed/36148073
http://dx.doi.org/10.3389/fcvm.2022.988799
work_keys_str_mv AT guoxueyuan multimorbiditypolypharmacyandinappropriateprescribinginelderlypatientswithatrialfibrillationareportfromthechinaatrialfibrillationregistrystudy
AT limengmeng multimorbiditypolypharmacyandinappropriateprescribinginelderlypatientswithatrialfibrillationareportfromthechinaatrialfibrillationregistrystudy
AT duxin multimorbiditypolypharmacyandinappropriateprescribinginelderlypatientswithatrialfibrillationareportfromthechinaatrialfibrillationregistrystudy
AT jiangchenxi multimorbiditypolypharmacyandinappropriateprescribinginelderlypatientswithatrialfibrillationareportfromthechinaatrialfibrillationregistrystudy
AT lisongnan multimorbiditypolypharmacyandinappropriateprescribinginelderlypatientswithatrialfibrillationareportfromthechinaatrialfibrillationregistrystudy
AT tangribo multimorbiditypolypharmacyandinappropriateprescribinginelderlypatientswithatrialfibrillationareportfromthechinaatrialfibrillationregistrystudy
AT sangcaihua multimorbiditypolypharmacyandinappropriateprescribinginelderlypatientswithatrialfibrillationareportfromthechinaatrialfibrillationregistrystudy
AT yuronghui multimorbiditypolypharmacyandinappropriateprescribinginelderlypatientswithatrialfibrillationareportfromthechinaatrialfibrillationregistrystudy
AT longdeyong multimorbiditypolypharmacyandinappropriateprescribinginelderlypatientswithatrialfibrillationareportfromthechinaatrialfibrillationregistrystudy
AT dongjianzeng multimorbiditypolypharmacyandinappropriateprescribinginelderlypatientswithatrialfibrillationareportfromthechinaatrialfibrillationregistrystudy
AT machangsheng multimorbiditypolypharmacyandinappropriateprescribinginelderlypatientswithatrialfibrillationareportfromthechinaatrialfibrillationregistrystudy